Patent application number | Description | Published |
20110087920 | COMPUTING DEVICE WITH RECOVERY MODE - Methods and apparatus for implementing a recovery mode procedure for a computing device are disclosed. An example method includes determining, by a computing device, that a recovery mode procedure is to be executed on the computing device. The example method further includes, determining whether a trusted recovery image is accessible to the computing device and, in the event the trusted recovery image is accessible to the computing device, executing the recovery mode procedure to repair or replace a current image of the computing device using the trusted recovery image. In the event the trusted recovery image is not accessible to the computing device, the example method includes, providing instructions for obtaining the trusted recovery image, determining the obtained trusted recovery image is accessible to the computing device and executing the recovery mode procedure to repair or replace the current image of the computing device using the obtained trusted recovery image. | 04-14-2011 |
20150254198 | METHODS AND APPARATUS RELATED TO BUS ARBITRATION WITHIN A MULTI-MASTER SYSTEM - In one generic aspect, a bus system for bus arbitration is disclosed. The bus system may include a first master device, a second master device, a bus connected to the first master device and the second master device, and a plurality of arbitration lines including a first master claim line associated with the first master device, and a second master claim line associated with the second master device. Each of the first master claim line and the second master claim line may be connected to the first master device and the second master device. | 09-10-2015 |
Patent application number | Description | Published |
20090155824 | METHODS FOR ANTIBODY ENGINEERING - The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications. | 06-18-2009 |
20120003671 | METHODS FOR ANTIBODY ENGINEERING - The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications. | 01-05-2012 |
20120329069 | METHODS FOR ANTIBODY ENGINEERING - The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications. | 12-27-2012 |
Patent application number | Description | Published |
20090202558 | TNFalpha-NEUTRALIZING ANTIBODIES - The invention provides monoclonal antibodies that neutralize TNFα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNFα activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications. | 08-13-2009 |
20110243936 | TNFalpha-NEUTRALIZING ANTIBODIES - The invention provides monoclonal antibodies that neutralize TNFα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNFα activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications. | 10-06-2011 |
20120269809 | TNFalpha-Neutralizing Antibodies - The invention provides monoclonal antibodies that neutralize TNFα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNFα activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications. | 10-25-2012 |
20150038370 | Methods for Antibody Engineering - The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications. | 02-05-2015 |
Patent application number | Description | Published |
20090215724 | Pyrrolopyrazine kinase inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, | 08-27-2009 |
20090215750 | Pyrrolopyrazine kinase inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, | 08-27-2009 |
20090215785 | Pyrrolopyrazine kinase inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, | 08-27-2009 |
20090215788 | Pyrrolopyrazine kinase inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, | 08-27-2009 |
20100267666 | Pyrrolopyrazine kinase inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, | 10-21-2010 |
20110070190 | HETEROCYCLIC ANTIVIRAL COMPOUNDS - The invention discloses 1-N-substituted-6-(hetero)aryl-1H-thieno[3,2-d]pyrimidin-4-one derivatives of formula | 03-24-2011 |
20110230414 | Pyrrolopyrazine Kinase Inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, | 09-22-2011 |
20110230462 | Pyrrolopyrazine Kinase Inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, | 09-22-2011 |
20110288067 | Pyrrolopyrazine Kinase Inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, | 11-24-2011 |
20110288097 | Pyrrolopyrazine Kinase Inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, | 11-24-2011 |
20140155376 | PYRROLOPYRAZINE KINASE INHIBITORS - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, | 06-05-2014 |
20150072982 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF - Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compounds. Examples of an orthomyxovirus viral infection include an influenza infection. | 03-12-2015 |
Patent application number | Description | Published |
20110159551 | cDNA SYNTHESIS USING A REVERSIBLY INACTIVATED REVERSE TRANSCRIPTASE - The present invention provides compositions and methods for a reverse transcription reaction using a reversibly inactivated reverse transcriptase enzyme. The reversibly inactivated reverse transcriptase enzyme results from a chemical modification which inactivates the reverse transcriptase enzyme. The activity of the reverse transcriptase enzyme is recovered by an incubation of the reaction mixture at elevated temperature prior to, or as part of the reverse transcription reaction. The reverse transcriptase enzyme of the present invention provides for a signficant reduction in non-specific reverse transcription from template nucleic acid molecules because the formulation of the reaction mixture does not support the formation of reverse transcription products prior to activation of the reverse transcriptase. | 06-30-2011 |
20120196294 | WORKFLOW FOR DETECTION OF LIGANDS USING NUCLEIC ACIDS - This application relates to methods for ligating oligonucleotides having complementarity to a target nucleic acid, and amplifying the ligated oligonucleotides, where ligation and amplification occur in the same reaction mixture. | 08-02-2012 |
20120196329 | POLYMERIZATION OF NUCLEIC ACIDS USING ACTIVATION BY POLYPHOSPHOROLYSIS (APP) REACTIONS - This disclosure relates to methods of performing activation by polyphosphorolysis (APP) reactions using at least one of the polyphosphorylating agents triphosphate, polyphosphate, imidodiphosphate, thiodiphosphate (or μ-monothiopyrophosphate), and related compounds. | 08-02-2012 |
20140234940 | MUTANT RB69 DNA POLYMERASE - Provided herein are mutant DNA-dependent polymerases which are derived from, or otherwise related to, wild type RB69 DNA polymerase. These mutant polymerases are capable of selectively binding labeled nucleotides. These mutant polymerases are also capable of incorporating a variety of naturally occurring and modified nucleotides, including, for example, terminator nucleotides. | 08-21-2014 |
20140378315 | ENZYMATIC LIGATION OF NUCLEIC ACIDS - Methods, assays, compositions and kits for the ligation of short polynucleotides are presented herein. The short polynucleotides are optionally no more than 7 nucleotides in length, and can be as short as 3 or 4 nucleotides in length. The ligation is optionally performed by CV ligase. | 12-25-2014 |
20150191775 | POLYMERIZATION OF NUCLEIC ACIDS USING ACTIVATION BY POLYPHOSPHOROLYSIS (APP) REACTIONS - This disclosure relates to methods of performing activation by polyphosphorolysis (APP) reactions using at least one of the polyphosphorylating agents triphosphate, polyphosphate, imidodiphosphate, thiodiphosphate (or μ-monothiopyrophosphate), and related compounds. | 07-09-2015 |
Patent application number | Description | Published |
20100311144 | MUTANT DNA POLYMERASES - Provided herein are mutant DNA-dependent polymerases which are derived from, or otherwise related to, wild type RB69 DNA polymerase. These mutant polymerases are capable of selectively binding labeled nucleotides. These mutant polymerases are also capable of incorporating a variety of naturally occurring and modified nucleotides, including, for example, terminator nucleotides. | 12-09-2010 |
20110014612 | POLYMERASE COMPOSITIONS & METHODS - Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of making and using such compositions. In some embodiments, the compositions exhibit altered properties that can enhance their utility in a variety of biological applications. Such altered properties, can include, for example, altered nucleotide binding affinities, altered nucleotide incorporation kinetics, altered photostability and/or altered nanoparticle tolerance, as well as a range of other properties as disclosed herein. | 01-20-2011 |
20120070838 | Polymerase Assay with a FRET Substrate - This specification generally relates to non-radioactive methods of detecting nucleic acid polymerase activity and methods of detecting compounds that modulate nucleic acid polymerase activity. The activity may be measured in real-time using a real-time PCR instrument. | 03-22-2012 |
20120322057 | POLYMERASE COMPOSITIONS AND METHODS - Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of making and using such compositions. In some embodiments, the compositions exhibit altered properties that can enhance their utility in a variety of biological applications. Such altered properties, can include, for example, altered nucleotide binding affinities, altered nucleotide incorporation kinetics, altered photostability and/or altered nanoparticle tolerance, as well as a range of other properties as disclosed herein. | 12-20-2012 |
20130005020 | MUTANT DNA POLYMERASES - Provided herein are mutant DNA-dependent polymerases which are derived from, or otherwise related to, wild type RB69 DNA polymerase. These mutant polymerases are capable of selectively binding labeled nucleotides. These mutant polymerases are also capable of incorporating a variety of naturally occurring and modified nucleotides, including, for example, terminator nucleotides. | 01-03-2013 |
20150247136 | POLYMERASE COMPOSITIONS AND METHODS - Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of making and using such compositions. In some embodiments, the compositions exhibit altered properties that can enhance their utility in a variety of biological applications. Such altered properties, can include, for example, altered nucleotide binding affinities, altered nucleotide incorporation kinetics, altered photostability and/or altered nanoparticle tolerance, as well as a range of other properties as disclosed herein. | 09-03-2015 |